|Bid||81.79 x 900|
|Ask||81.84 x 800|
|Day's Range||81.09 - 81.98|
|52 Week Range||72.30 - 94.19|
|PE Ratio (TTM)||23.99|
|Forward Dividend & Yield||2.98 (3.85%)|
|1y Target Est||89.75|
Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter compared to $1.22 billion in the second quarter of 2017, reflecting a ~1% YoY (year-over-year) fall. However, Bausch + Lomb witnessed ~4% YoY organic growth in the second quarter.
Durham County approved incentives worth nearly $450,000 combined Monday, including a package solidifying gene therapy firm AveXis’ 200-job expansion in the Triangle.
Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
Novartis (NOVN.S) has recruited a new chief ethics officer from Siemens (SIEGn.DE) after costly bribery scandals and a disputed $1.2 million (938,673.3 pounds) contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake. Novartis said on Tuesday it had hired Klaus Moosmayer, 49, from Siemens, where he spent more than a decade helping oversee the German engineering company's efforts to build its compliance system after several of its own bribery scandals. Novartis Chief Executive Vas Narasimhan, promoted on Feb. 1 to lead the Basel-based company, has promised to boost its reputation following settlements or fines in corruption cases in China, South Korea and the United States.
Novartis (NOVN.S) has recruited a new chief ethics officer from Siemens (SIEGn.DE) after costly bribery scandals and a disputed $1.2 million contract with President Donald Trump's former lawyer that the Swiss drugmaker now calls a mistake. Novartis said on Tuesday it had hired Klaus Moosmayer, 49, from Siemens, where he spent more than a decade helping oversee the German engineering company's efforts to build its compliance system after several of its own bribery scandals. Novartis Chief Executive Vas Narasimhan, promoted on Feb. 1 to lead the Basel-based company, has promised to boost its reputation following settlements or fines in corruption cases in China, South Korea and the United States.
In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million. The company has projected a single-digit effective tax rate for Q3 2018. In fiscal 2018, analysts expect OPKO Health’s adjusted diluted EPS to rise ~51.0% to -$0.24, while peers Novartis (NVS), Merck (MRK), and Regeneron (REGN) are expected to report adjusted diluted EPS of approximately $5.20, $2.60, and $20.40, respectively.
Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO at $18 per share. The Analysts ...
In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes. Meanwhile, the company expects product revenue of $28 million–$32 million, and Rayaldee revenue of $5.7 million–$6.5 million.
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.
Xencor stock popped to a record high Tuesday on investor excitement for the biotech company's inflammation and cancer drugs, though it reported no revenue for the second quarter.
How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.
As we discussed earlier, Pfizer’s (PFE) business is separated into two segments: Innovative Health and Essential Health. The Innovative Health segment contributes over 61.4% of Pfizer’s total revenue. This rise included a 5% rise in operating revenue and a 3% favorable impact of foreign exchange.
Yesterday, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new vial presentation and indication in pediatric patients aged one month or older. Granix is a short-acting G-CSF (granulocyte colony-stimulating factor) that was approved by the FDA in 2012 for use in adults.
On August 3, Mylan (MYL) stock ended the trading day at $38.45 per share, rising ~5.3% compared to the previous day’s closing price. Mylan released its Q1 2018 earnings results on May 9. Mylan is also facing some supply constraints for the EpiPen, its allergy product, due to supply delays from Pfizer (PFE).
Mylan (MYL), one of the leading pharmaceutical companies and the manufacturer of the EpiPen, is set to announce its Q2 2018 earnings results on August 8. In Q1 2018, it barely met analysts’ estimates. It delivered a dismal performance in 2017 with a marginal improvement in the first quarter of 2018.
Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.